Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 367

1.
2.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
3.
4.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
5.
6.

[Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].

Riva L, Di Pasquale G, Casella G, Calabrese D, Zagnoni S, Pallotti MG.

G Ital Cardiol (Rome). 2010 Dec;11(12 Suppl 3):27S-33S. Italian.

PMID:
21491737
7.

Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome.

Dobesh PP, Phillips KW, Haines ST.

Am J Health Syst Pharm. 2008 Aug 1;65(15 Suppl 7):S22-8. doi: 10.2146/ajhp080242.

PMID:
18653821
8.
10.

A risk score to predict bleeding in patients with acute coronary syndromes.

Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.

11.

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.

PMID:
18319394
12.

Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.

Lefebvre CW, Hoekstra JW, Bonaca M, Giugliano R.

J Emerg Med. 2009 Feb;36(2):162-70. doi: 10.1016/j.jemermed.2007.10.020. Epub 2008 Mar 19.

PMID:
18353601
13.

Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.

Pollack CV Jr, Hollander JE.

J Emerg Med. 2008 Jul;35(1):5-13. doi: 10.1016/j.jemermed.2007.09.032. Epub 2008 Mar 24. Review.

PMID:
18359601
14.

Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.

Manoukian SV.

Am J Cardiol. 2009 Sep 7;104(5 Suppl):9C-15C. doi: 10.1016/j.amjcard.2009.06.020. Review.

PMID:
19695355
15.

Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.

Reny JL, Bonvini RF, Bonvini JM, Roffi M, Fontana P.

Cardiovasc Ther. 2012 Feb;30(1):e41-50. doi: 10.1111/j.1755-5922.2010.00248.x. Epub 2010 Nov 14. Review.

PMID:
21073667
16.

Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.

Becker RC, Gibson CM, Jennings LK, Morrow DA.

Am J Cardiol. 2010 Oct 15;106(8):S2-3. doi: 10.1016/j.amjcard.2010.08.026.

PMID:
20920638
17.
18.

Thienopyridine antiplatelet agents: focus on prasugrel.

Freeman MK.

Consult Pharm. 2010 Apr;25(4):241-57. doi: 10.4140/TCP.n.2010.241. Review.

PMID:
20511177
19.

Emerging oral antiplatelet therapies for acute coronary syndromes.

Pollack CV Jr.

Hosp Pract (1995). 2010 Nov;38(4):29-37. doi: 10.3810/hp.2010.11.337.

PMID:
21068524
20.

Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

Martin MT, Spinler SA, Nutescu EA.

Clin Ther. 2011 Apr;33(4):425-42. doi: 10.1016/j.clinthera.2011.04.007. Review.

PMID:
21635989

Supplemental Content

Support Center